Glaukos Corp. (NYSE:GKOS) has been assigned a consensus recommendation of “Buy” from the seven research firms that are currently covering the company. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $38.80.

GKOS has been the subject of several research analyst reports. Cantor Fitzgerald lifted their target price on shares of Glaukos Corp. to $45.00 in a report on Friday, November 11th. Piper Jaffray Cos. lifted their target price on shares of Glaukos Corp. to $42.00 in a report on Tuesday, August 2nd. Zacks Investment Research raised shares of Glaukos Corp. from a “hold” rating to a “buy” rating and set a $37.00 target price for the company in a report on Thursday, August 4th. Roth Capital lifted their target price on shares of Glaukos Corp. from $36.50 to $41.00 and gave the stock a “buy” rating in a report on Tuesday, August 2nd. Finally, Stifel Nicolaus reaffirmed a “hold” rating on shares of Glaukos Corp. in a report on Tuesday, September 27th.

Shares of Glaukos Corp. (NYSE:GKOS) traded down 1.18% during mid-day trading on Monday, reaching $32.80. 99,952 shares of the company’s stock traded hands. The stock has a market cap of $1.10 billion, a PE ratio of 575.44 and a beta of 1.45. The firm has a 50 day moving average price of $35.03 and a 200-day moving average price of $31.40. Glaukos Corp. has a 12 month low of $14.25 and a 12 month high of $39.82.

Glaukos Corp. (NYSE:GKOS) last announced its quarterly earnings data on Thursday, November 10th. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of $0.00 by $0.03. The company earned $29.60 million during the quarter, compared to the consensus estimate of $27.21 million. Glaukos Corp. had a net margin of 2.07% and a return on equity of 2.05%. The company’s quarterly revenue was up 55.8% on a year-over-year basis. During the same quarter last year, the firm posted ($0.07) EPS. On average, analysts predict that Glaukos Corp. will post $0.12 earnings per share for the current fiscal year.

In other news, CEO Thomas William Burns sold 200,120 shares of the business’s stock in a transaction that occurred on Tuesday, November 15th. The shares were sold at an average price of $33.68, for a total value of $6,740,041.60. Following the completion of the transaction, the chief executive officer now directly owns 1,388 shares in the company, valued at approximately $46,747.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Chris M. Calcaterra sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, October 24th. The shares were sold at an average price of $36.01, for a total transaction of $720,200.00. Following the completion of the transaction, the insider now owns 260,000 shares of the company’s stock, valued at $9,362,600. The disclosure for this sale can be found here. 36.80% of the stock is currently owned by company insiders.

Institutional investors have recently modified their holdings of the stock. Credit Suisse AG boosted its position in shares of Glaukos Corp. by 496.9% in the third quarter. Credit Suisse AG now owns 74,648 shares of the company’s stock valued at $2,817,000 after buying an additional 62,143 shares during the last quarter. Bamco Inc. NY boosted its position in shares of Glaukos Corp. by 381.8% in the third quarter. Bamco Inc. NY now owns 115,261 shares of the company’s stock valued at $4,350,000 after buying an additional 91,336 shares during the last quarter. Picton Mahoney Asset Management boosted its position in shares of Glaukos Corp. by 474.6% in the third quarter. Picton Mahoney Asset Management now owns 40,800 shares of the company’s stock valued at $1,540,000 after buying an additional 33,700 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Glaukos Corp. during the third quarter valued at approximately $263,000. Finally, D. E. Shaw & Co. Inc. boosted its position in shares of Glaukos Corp. by 19.6% in the third quarter. D. E. Shaw & Co. Inc. now owns 20,486 shares of the company’s stock valued at $773,000 after buying an additional 3,361 shares during the last quarter. Institutional investors own 73.87% of the company’s stock.

Glaukos Corp. Company Profile

Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent, an MIGS device measuring approximately one millimeter long and approximately 0.33 millimeter wide.

5 Day Chart for NYSE:GKOS

Receive News & Stock Ratings for Glaukos Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corp. and related stocks with our FREE daily email newsletter.